field out of the water on the opening stage with a mind-boggling time-trial, which included a 55km/h average pace, 59km/h for the 16km flat section, a sub-17 minute time for opening 10 miles, and six KOMs out of seven segments — but yesterday, it was less than a tenth of a second that separated him from victory.Evenepoel began strongly, already up on Roglič by almost half a minute by the first checkpoint.
If you don’t want to subscribe, please turn your ad blocker off. The revenue from adverts helps to fund our site.If you’ve enjoyed this article, then please consider subscribing to road.cc from as little as £1.99. Our mission is to bring you all the news that’s relevant to you as a cyclist, independent reviews, impartial buying advice and more. Your subscription will help us to do more.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Remco Evenepoel wins time trial stage by 0.09 seconds at Giro d’ItaliaThe Belgian once again put in a strong display to JUST edge out Wales' Geraint Thomas at the time trial as he regained his lead at the top of the Italian Grand Tour
Source: roadcc - 🏆 21. / 71 Read more »
Remco Evenepoel wins time trial stage by ONE second at Giro d’ItaliaIs anyone surprised? Evenepoel takes Giro d'Italia stage 9 victory by ONE second, beating Geraint Thomas in another strong time trial showing cycling
Source: roadcc - 🏆 21. / 71 Read more »
Oxford care home residents trial virtual reality walkingTwo care homes in Oxford trial VR headsets that allow residents to explore real places.
Source: BBCTech - 🏆 81. / 55 Read more »
The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial - Immunity & AgeingBackground Aging is associated with progressive declines in immune responses leading to increased risk of severe infection and diminished vaccination responses. Influenza (flu) is a leading killer of older adults despite availability of seasonal vaccines. Geroscience-guided interventions targeting biological aging could offer transformational approaches to reverse broad declines in immune responses with aging. Here, we evaluated effects of metformin, an FDA approved diabetes drug and candidate anti-aging drug, on flu vaccination responses and markers of immunological resilience in a pilot and feasibility double-blinded placebo-controlled study. Results Healthy older adults (non-diabetic/non-prediabetic, age: 74.4 ± 1.7 years) were randomized to metformin (n = 8, 1500 mg extended release/daily) or placebo (n = 7) treatment for 20 weeks and were vaccinated with high-dose flu vaccine after 10 weeks of treatment. Peripheral blood mononuclear cells (PBMCs), serum, and plasma were collected prior to treatment, immediately prior to vaccination, and 1, 5, and 10 weeks post vaccination. Increased serum antibody titers were observed post vaccination with no significant differences between groups. Metformin treatment led to trending increases in circulating T follicular helper cells post-vaccination. Furthermore, 20 weeks of metformin treatment reduced expression of exhaustion marker CD57 in circulating CD4 T cells. Conclusions Pre-vaccination metformin treatment improved some components of flu vaccine responses and reduced some markers of T cell exhaustion without serious adverse events in nondiabetic older adults. Thus, our findings highlight the potential utility of metformin to improve flu vaccine responses and reduce age-related immune exhaustion in older adults, providing improved immunological resilience in nondiabetic older adults.
Source: BioMedCentral - 🏆 22. / 71 Read more »
Effect of intradialytic oral nutritional supplementation on nutritional markers in malnourished chronic hemodialysis patients: prospective randomized trial - BMC NephrologyBackground and objectives Malnutrition is prevalent in chronic hemodialysis (HD) patients. It increases mortality and negatively affects quality of life. This study aimed to assess the effect of intradialytic oral nutritional supplement (ONS) on nutritional markers in chronic HD patients with protein energy wasting (PEW). Methods This 3-month prospective, open-label, randomized controlled trial included 60 chronic HD patients with PEW. The intervention group (30 patients) received intradialytic ONS and dietary counseling, whereas the control group (30 patients) received only dietary counseling. Nutritional markers were measured at the beginning and end of the study. Results The mean age of the patients was 54 ± 12.7 years, and that of the HD vintage was 64 ± 49.3 months. Compared to the control group, the intervention group showed a significant increase in serum albumin (p | 0.001), prealbumin (p | 0.001), cholesterol (p = 0.016), body mass index (BMI) (p = 0.019), serum creatinine/body surface area (BSA) (p = 0.016), and composite French PEW score (p=0.002), as well as a significant decrease in high-sensitivity C-reactive protein (hs-CRP) (p=0.001). The total iron binding capacity, normalized protein nitrogen appearance, and hemoglobin levels increased significantly in both groups. Conclusion Intradialytic ONS and dietary counseling for three months were more effective than dietary counseling alone in terms of improving nutritional status and inflammation in chronic HD patients, as evidenced by increases in serum albumin, prealbumin, BMI, serum creatinine/BSA, composite French PEW score, and a decrease in hs-CRP.
Source: BioMedCentral - 🏆 22. / 71 Read more »